Biopharmaceutical company Bristol-Myers Squibb Co. (BMY) announced Tuesday that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Opdivo (nivolumab) flat dosing schedule of 240 mg infused over 30 minutes every two weeks (Q2W) or 480 mg infused over 60 minutes every four weeks (Q4W).
from RTT - Biotech https://ift.tt/2l9zOI4
via IFTTT
No comments:
Post a Comment